[{"data":1,"prerenderedAt":283},["ShallowReactive",2],{"story-31527-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":49,"questions":50,"relatedArticles":60,"body_color":281,"card_color":282},"31527",null,"Pharma M&A Signals Health Product Boom for E-Commerce","- $2.2B Deal Unlocks $500M Potential in Specialized Health Markets",[],[10,11,12,13,14,12,15,16,17,18,19,12,20,21,22,23,24,25,26,27,28,29,28,30,31,28,32,33,34,29,35,36,37,38,39,40,41,42,43,44,45,46,47,29,42,48],"https://media.raps.org/m/6546510458fb6d71/webimage-Regulatory-Recon-Icon.png","https://static.law360news.com/images/law360_square_logo_2021.png","https://images.mktw.net/im-13038847?width=1260&height=840","https://i.guim.co.uk/img/media/5a02923e7915fa57f30b9a37ccdce5d8011acb7c/0_0_1000_800/master/1000.jpg?width=465&dpr=1&s=none&crop=none","https://s.yimg.com/ny/api/res/1.2/kC_3xES9FDr75r2LFOCWeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/pharmaceutical_technology_376/9a24f9b965fec5d43729f160b6ff86f0","https://contenthub.lw.com/api/public/content/7e048001e327404891db2cc03295e8f9?v=de62d716&t=750x225","https://s.yimg.com/ny/api/res/1.2/govdECs8BohCywMj_ApURQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/b20e725252aeaec7b691cdd58b1dab6f","https://www.statnews.com/wp-content/uploads/2024/05/GettyImages-1238133958-645x645.jpg","https://www.genengnews.com/wp-content/uploads/2026/01/GSK-ware_1_2025_lab_043_hess-JPG.jpg","https://www.manilatimes.net/manilatimes/uploads/images/2026/01/21/906616.png","https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Target-and-dart.webp?t=1588276872","http://www.thewestonmercury.co.uk/resources/images/20442079.jpg/","https://blog.tipranks.com/wp-content/uploads/2025/09/shutterstock_1859342764-750x406.jpg","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F852093%2Fmedical-researchers-gettyimages-675577941.jpg&w=1200&op=resize","https://media.bizj.us/view/img/12203316/bw-054*900xx2294-1292-0-30.jpg","https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg","https://cdn.benzinga.com/files/images/story/2026/01/20/Section-Of-A-Financial-Newspaper-Titled-.jpeg?width=1200&height=800&fit=crop","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://images.barrons.com/im-367183?width=700&height=466","https://www.thetimes.com/imageserver/image/%2F186f14d4-5ef5-48f9-a2c4-283e32779ef8.jpg?crop=3654%2C2055%2C0%2C192&resize=1200","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Fc21f9b8d-42a3-4100-9f70-3feb1b423829.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://cdn.sanity.io/images/0vv8moc6/pharmexec/69f856c71f92fb3f1bd17f365880fff6f9bd8e41-1667x1668.jpg","https://usaherald.com/wp-content/uploads/2026/01/GSK-Bets-2.2-Billion-on-Breakthrough-Allergy-Drug-as-Big-Pharma-Races-for-Next-Immunology-Blockbuster.png","http://www.eveningnews24.co.uk/resources/images/20442079.jpg/","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iDykJNtVVjGo/v1/1200x800.jpg","https://cdn.zonebourse.com/static/resize/768/432//images//reuters/2025-04-30T061040Z_1_LYNXMPEL3T07L_RTROPTP_4_GSK-RESULTS.JPG","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GSK%20ESMO.jpg?VersionId=cPXHRHPjNhePLQmiX0RePvDyiWbWN73E","https://www.becclesandbungayjournal.co.uk/resources/images/20442079.jpg?type=og-image","https://www.investors.com/wp-content/uploads/2024/02/Stock-Raptfda-shutt.jpg","https://endpoints.news/wp-content/uploads/2023/11/Brian-Wong-RAPT-Therapeutics-tile1.jpg","https://www.livemint.com/lm-img/img/2026/01/20/1600x900/logo/g36fc1154c7791565f05a2cc0e38f6b34af5461c090bbbbfff_1734490184268_1768901281057.png","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1UzjEX.img?w=768&h=432&m=6","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F852093%2Fmedical-researchers-gettyimages-675577941.jpg&w=700","https://static.gurufocus.com/logos/0C000007W1.png?20","https://www.livemint.com/lm-img/img/2026/01/20/1600x900/logo/INDIA-US-TARIFF-TRADE-PHARMACEUTICAL-5_17592418593_1768900444617_1768900444787.jpg","https://newsfile.futunn.com/news-thumbnail/20240724/public/17218233095263946625274-news-thumbnail/20240724/public/1721823309526668798059.jpg","https://d2iztrg3kgqpue.cloudfront.net/production/df2ef00a-e536-4002-aad7-ba4f705b10b3.png","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247134002/image_2247134002.jpg?io=getty-c-w630","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg?io=getty-c-w1280","**Pharmaceutical innovation is creating massive opportunities for cross-border e-commerce sellers in specialized health product categories.** GSK's $2.2 billion acquisition of RAPT Therapeutics represents a strategic pivot that will reshape health and wellness market dynamics, offering sophisticated sellers multiple entry points for targeted merchandise.\n\n**The food allergy treatment market represents a $1.5 billion global opportunity with significant e-commerce potential.** With 17 million diagnosed food allergy patients in the United States alone, and 1.3 million experiencing severe reactions, this acquisition signals an emerging product ecosystem. The ozureprubart treatment's unique quarterly dosing schedule suggests complementary product opportunities in:\n- Specialized nutritional supplements\n- Allergy-friendly food products\n- Medical tracking and management tools\n- Child-focused health monitoring devices\n\n**Strategic implications for international sellers include:**\n- Expanding health-focused product catalogs\n- Developing niche, condition-specific merchandise\n- Creating bundled wellness solutions\n- Targeting pediatric and adolescent consumer segments\n\nThe pharmaceutical landscape is rapidly transforming, with large companies like GSK investing heavily in targeted medical innovations. For e-commerce sellers, this represents a critical signal to develop more sophisticated, scientifically-backed product offerings that address specific medical needs with precision and expertise.",[51,54,57],{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"What trends are emerging in pharmaceutical e-commerce?","Large pharmaceutical companies are investing in targeted medical innovations, signaling a shift towards precision health solutions. E-commerce sellers should focus on developing niche, scientifically-validated products that address specific medical conditions.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"What market size exists for food allergy-related products?","The global food allergy market is estimated at $1.5 billion, with significant growth potential. 65% of severe food allergy patients are children and adolescents, creating a substantial target demographic for specialized health products.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How can e-commerce sellers capitalize on the GSK-RAPT Therapeutics acquisition?","Sellers can develop complementary products like specialized nutritional supplements, allergy-friendly foods, medical tracking tools, and pediatric health management devices. Focus on scientifically-backed, condition-specific merchandise targeting the 17 million food allergy patients in the US market.",[61,66,70,74,78,82,86,89,93,96,100,104,108,112,115,119,123,127,131,135,138,142,146,150,153,156,159,163,167,171,176,179,183,187,190,194,198,201,204,208,212,216,220,224,228,232,236,240,243,246,249,253,257,261,265,269,273,277],{"id":62,"title":63,"source":64,"logo":41,"time":65},268379,"RAPT Therapeutics stock surges 63% in pre-market trade on Nasdaq after GSK's $2.2 billion acquisition deal","https://www.msn.com/en-in/news/other/rapt-therapeutics-stock-surges-63-in-pre-market-trade-on-nasdaq-after-gsk-s-2-2-billion-acquisition-deal/ar-AA1UzgWn","2天前",{"id":67,"title":68,"source":69,"logo":23,"time":65},268378,"Why Rapt Therapeutics Stock Soared Today","https://www.fool.com/investing/2026/01/20/why-rapt-therapeutics-stock-is-up-today/",{"id":71,"title":72,"source":73,"logo":21,"time":65},270297,"GSK acquiring firm developing food allergy treatment in £1.6bn deal","https://www.thewestonmercury.co.uk/news/national/25779311.gsk-acquiring-firm-developing-food-allergy-treatment-1-6bn-deal/",{"id":75,"title":76,"source":77,"logo":28,"time":65},270296,"This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.","https://www.barrons.com/articles/rapt-therapeutics-stock-gsk-acquisition-9ab8074f?gaa_at=eafs&gaa_n=AWEtsqeYrb8eTtNXyMumkWEYmqhpjTLmHHN6puU2QsRSjAgSEPLdoV-YeXab&gaa_ts=69708c4f&gaa_sig=Vc1-0_zTtoD5XZrxf4fwB2vBPvuOh2ASEQex7SDoHzXTJ2TzMt-SWRIGSDpo8zV0T6gmSbjmv3EAxNoXW0Wkmw%3D%3D",{"id":79,"title":80,"source":81,"logo":29,"time":65},270295,"GSK to buy US food allergy specialist for $2.2bn","https://www.thetimes.com/business/companies-markets/article/gsk-acquisition-buys-rapt-us-luke-miels-3jh3f0n0d?gaa_at=eafs&gaa_n=AWEtsqcsRqFxmXgZ-tG2OVSav-_gW9Ap0vx99KMyYyoVj28mRbS5Fkf8hJXX&gaa_ts=69708c4f&gaa_sig=byTnyqddZOr0qqVx9L48JqUg_4pra1UrtyQCR7kpQhbGc5fFYQbQYmdb8CEQbCknJmAuCru4mOt_nfJQDe9N4Q%3D%3D",{"id":83,"title":84,"source":85,"logo":12,"time":65},270294,"GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug","https://www.marketwatch.com/story/gsk-announces-2-2-billion-deal-targeting-once-per-three-month-food-allergy-drug-a376ec3b?gaa_at=eafs&gaa_n=AWEtsqc9MR9Q314OYrGh4iRkjQbi6xb7MA-h3uE5KX9GG41UooWRI8Rm7U_D&gaa_ts=69708c4f&gaa_sig=uJEi8U_Qj_flBP-4LHhNN5i_4HW3ooyP8Qnx4_hplfr0tJLyJ--6hlRW8ctP8RIU83V_24aaItwqG0wscXZeZQ%3D%3D",{"id":87,"title":68,"source":88,"logo":16,"time":65},270293,"https://finance.yahoo.com/news/why-rapt-therapeutics-stock-soared-223007759.html",{"id":90,"title":91,"source":92,"logo":43,"time":65},270292,"GSK to Acquire Rapt Therapeutics for $2.2 Billion","https://www.gurufocus.com/news/5595457/gsk-to-acquire-rapt-therapeutics-for-22-billion?mobile=true",{"id":94,"title":84,"source":95,"logo":12,"time":65},268380,"https://www.marketwatch.com/story/gsk-announces-2-2-billion-deal-targeting-once-per-three-month-food-allergy-drug-a376ec3b?gaa_at=eafs&gaa_n=AWEtsqfJuPxSIn7_VweCRLDq9agPSUx4MkEE1w765Ez41pw_G69gEUKc9j39&gaa_ts=69701bd2&gaa_sig=wHcu6B5EtYjVW4yOb7OCw3aFkoqv-VYpHLUjFTIT5UREs6hjDudzeouwEn16egZiRIQjX0aIViKV_TiogXKCfw%3D%3D",{"id":97,"title":98,"source":99,"logo":5,"time":65},269392,"Rapt Therapeutics stock rating downgraded to Hold by Clear Street after GSK deal","https://uk.investing.com/news/analyst-ratings/rapt-therapeutics-stock-rating-downgraded-to-hold-by-clear-street-after-gsk-deal-93CH-4460644",{"id":101,"title":102,"source":103,"logo":45,"time":65},269391,"GSK to Bolster Immunology Pipeline With $2.2 Billion Rapt Therapeutics Acquisition","https://news.futunn.com/en/post/67665559/gsk-to-bolster-immunology-pipeline-with-2-2-billion-rapt",{"id":105,"title":106,"source":107,"logo":36,"time":65},268386,"GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair","https://www.fiercebiotech.com/biotech/gsk-pays-22b-buy-rapt-its-phase-2-stage-food-allergy-challenger-xolair",{"id":109,"title":110,"source":111,"logo":15,"time":65},269398,"Latham & Watkins Advises on GSK’s US$2.2 Billion Acquisition of RAPT Therapeutics","https://www.lw.com/en/news/2026/01/latham-advises-on-gsks-us2-2-billion-acquisition-of-rapt-therapeutics",{"id":113,"title":76,"source":114,"logo":28,"time":65},268385,"https://www.barrons.com/articles/rapt-therapeutics-stock-gsk-acquisition-9ab8074f?gaa_at=eafs&gaa_n=AWEtsqfklcx_350dvVltLxcdnli_SpHppV4RwpDsLS-0hkxGFP0Vxt10h6U_&gaa_ts=69701bd2&gaa_sig=vDd2J8iL2AUfwmEtDUUIgxGE6an6NlxlRUHJ3i0XKwVDmgcwoMG_ljwxQTTgDAJCNVQxJs43SJnMeGCSVdEP5A%3D%3D",{"id":116,"title":117,"source":118,"logo":38,"time":65},269397,"GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout","https://www.investors.com/news/technology/rapt-stock-gsk-buyout/",{"id":120,"title":121,"source":122,"logo":22,"time":65},268388,"M&A News: GSK Bets Big on Food Allergy Drugs with $2.2B RAPT Therapeutics Deal","https://www.tipranks.com/news/ma-news-gsk-bets-big-on-food-allergy-drugs-with-2-2b-rapt-therapeutics-deal",{"id":124,"title":125,"source":126,"logo":34,"time":65},268387,"GSK to Buy Rapt Therapeutics in Deal Valued at $2.2 Billion","https://www.bloomberg.com/news/articles/2026-01-20/gsk-to-buy-rapt-therapeutics-in-deal-valued-at-2-2-billion",{"id":128,"title":129,"source":130,"logo":5,"time":65},269399,"GSK Acquires Forbion's RAPT Therapeutics for $2.2 Billion","https://intellectia.ai/news/stock/gsk-acquires-forbions-rapt-therapeutics-for-22-billion",{"id":132,"title":133,"source":134,"logo":26,"time":65},268382,"Why Rapt Therapeutics Shares Are Trading Higher By 63%; Here Are 20 Stocks Moving Premarket","https://www.benzinga.com/trading-ideas/movers/26/01/49995900/why-rapt-therapeutics-shares-are-trading-higher-by-63-here-are-20-stocks-moving-premarket",{"id":136,"title":84,"source":137,"logo":12,"time":65},269394,"https://www.marketwatch.com/story/gsk-announces-2-2-billion-deal-targeting-once-per-three-month-food-allergy-drug-a376ec3b?gaa_at=eafs&gaa_n=AWEtsqeR2mFBo6Dk2QnGo0y2FH7afQES6WWD6Oo18Qa-XpkPMYztNBKVb_a8&gaa_ts=69705513&gaa_sig=zNv7a6YX3cPsrXe4fLFuxj-Cc4FOsXUUpIm6LhjZgbWFRiuvRJqMjRCss5XtwboW5-eDMpqjDa_gYn-fyLbBsw%3D%3D",{"id":139,"title":140,"source":141,"logo":5,"time":65},268381,"RAPT Therapeutics stock soars 64% on GSK’s $2.2 billion acquisition offer","https://www.investing.com/news/stock-market-news/gsk-to-acquire-rapt-therapeutics-for-22-billion-4454027",{"id":143,"title":144,"source":145,"logo":10,"time":65},269393,"Recon: GSK to purchase RAPT Therapeutics, food allergy drugmaker, for $2.2 billion; Corvus’ therapy demonstrates positive results in early-stage eczema study","https://www.raps.org/news-and-articles/news-articles/2026/1/recon-gsk-to-purchase-rapt-therapeutics,-food-alle",{"id":147,"title":148,"source":149,"logo":31,"time":65},268384,"GSK's $2 Billion Acquisition of RAPT Therapeutics | PharmExec","https://www.pharmexec.com/view/daily-gsk-2-billion-acquisition-rapt-therapeutics",{"id":151,"title":76,"source":152,"logo":28,"time":65},269396,"https://www.barrons.com/articles/rapt-therapeutics-stock-gsk-acquisition-9ab8074f?gaa_at=eafs&gaa_n=AWEtsqev1GJBRiomTFElsfPzUrZsJ3OICTWrA3o77NNehmamH7wxEtqYdGmd&gaa_ts=69705513&gaa_sig=TtYMZ8RHki-5o0RAWB41grd3dMkeEvedcyh7n-BwK1RzGpTpK_B6p-07X8RT0Sw61wyo5_ROqzRkbS2v0yR0kA%3D%3D",{"id":154,"title":80,"source":155,"logo":29,"time":65},268383,"https://www.thetimes.com/business/companies-markets/article/gsk-acquisition-buys-rapt-us-luke-miels-3jh3f0n0d?gaa_at=eafs&gaa_n=AWEtsqc4nDQG5FLid14fnUlMf9oqTpN6jrPkDZEvIJtKnD0TIfDIqGfjlW9e&gaa_ts=69701bd2&gaa_sig=iVBpqj61kv-xAmaltWaXrdiJmo9TdI2I7c1MxSnLg479Ik_O6MihpR3puQsmYSUtaZPHKhuknKh278nxDex60Q%3D%3D",{"id":157,"title":80,"source":158,"logo":29,"time":65},269395,"https://www.thetimes.com/business/companies-markets/article/gsk-acquisition-buys-rapt-us-luke-miels-3jh3f0n0d?gaa_at=eafs&gaa_n=AWEtsqd5bK_GiAUdmJGUR-4vqVLUv4KBP1tZO6ILlN36MmTCAlOwQZ6WV4DI&gaa_ts=69705513&gaa_sig=uj096dFhLujP9lmL8Znli9gkDvQl6DrCJfvsY8RLgVv0A-NyB0zSeX9Orjgr_Rwtu9plFK6N1TikFTAOxH1H6g%3D%3D",{"id":160,"title":161,"source":162,"logo":13,"time":65},268368,"GSK to buy food allergy drug maker RAPT in $2.2bn deal","https://www.theguardian.com/business/2026/jan/20/gsk-buy-food-allergy-drug-maker-rapt-us-biotech",{"id":164,"title":165,"source":166,"logo":46,"time":65},268367,"Ibstock & GSK: Markets live blog","https://www.investorschronicle.co.uk/live-blog/636a8e98-7368-47e0-b26a-5a8c00202c0f",{"id":168,"title":169,"source":170,"logo":27,"time":65},268369,"RAPT Therapeutics Signs Multiple Material Agreements","https://www.tradingview.com/news/tradingview:e031c96b9cb4a:0-rapt-therapeutics-signs-multiple-material-agreements/",{"id":172,"title":173,"source":174,"logo":32,"time":175},270289,"GSK Bets $2.2 Billion on Breakthrough Allergy Drug as Big Pharma Races for Next Immunology Blockbuster","https://usaherald.com/gsk-bets-2-2-billion-on-breakthrough-allergy-drug-as-big-pharma-races-for-next-immunology-blockbuster/","1天前",{"id":177,"title":68,"source":178,"logo":5,"time":65},270291,"https://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/37138048/why-rapt-therapeutics-stock-soared-today/",{"id":180,"title":181,"source":182,"logo":25,"time":175},270290,"Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights","https://www.morningstar.com/news/pr-newswire/20260121ny67611/halper-sadeh-llc-encourages-cvgw-rapt-cflt-shareholders-to-contact-the-firm-to-discuss-their-rights",{"id":184,"title":185,"source":186,"logo":5,"time":65},268375,"A&O Shearman advises GSK on USD2.2 billion acquisition of RAPT Therapeutics","https://www.aoshearman.com/en/news/ao-shearman-advises-gsk-on-usd2-billion-acquisition-of-rapt-therapeutics",{"id":188,"title":68,"source":189,"logo":42,"time":65},268374,"https://www.nasdaq.com/articles/why-rapt-therapeutics-stock-soared-today",{"id":191,"title":192,"source":193,"logo":35,"time":65},268377,"GSK: shareholders urge company to step up reinvention","https://www.marketscreener.com/news/gsk-shareholders-urge-company-to-step-up-reinvention-ce7e58dcdc8cf622",{"id":195,"title":196,"source":197,"logo":20,"time":65},268376,"GSK gaining Rapt’s allergy drug in $2.2B M&A","https://www.bioworld.com/articles/728130-gsk-gaining-rapts-allergy-drug-in-22b-m-and-a",{"id":199,"title":68,"source":200,"logo":42,"time":65},268371,"https://finviz.com/news/281636/why-rapt-therapeutics-stock-soared-today",{"id":202,"title":68,"source":203,"logo":5,"time":65},268370,"https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/37138048/why-rapt-therapeutics-stock-soared-today/",{"id":205,"title":206,"source":207,"logo":39,"time":65},268373,"GSK makes $2.2B deal for RAPT and its food allergy candidate","https://endpoints.news/gsk-makes-2-2b-deal-for-rapt-and-its-food-allergy-candidate/",{"id":209,"title":210,"source":211,"logo":5,"time":65},268372,"GSK Broadens Immune Science Reach With Strategic Biotech Move","https://kalkinemedia.com/uk/stocks/metals-and-mining/gsk-broadens-immune-science-reach-with-strategic-biotech-move",{"id":213,"title":214,"source":215,"logo":5,"time":65},268438,"GSK enters agreement to acquire RAPT Therapeutics","https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/",{"id":217,"title":218,"source":219,"logo":30,"time":65},268437,"GSK to buy US biotech behind food allergy drug for $2.2bn","https://www.ft.com/content/80a5f5fc-59e0-4969-803e-7fd50e4812ba",{"id":221,"title":222,"source":223,"logo":5,"time":65},268436,"GSK scoops up RAPT Therapeutics for $2.2bn","https://www.pharmaceutical-technology.com/news/gsk-rapt-therapeutics-acquisition-2-2bn-immunology-food-allergy/",{"id":225,"title":226,"source":227,"logo":11,"time":65},268364,"A&O Shearman Steers GSK's $2.2B Rapt Therapeutics Deal","https://www.law360.com/articles/2431697/a-o-shearman-steers-gsk-s-2-2b-rapt-therapeutics-deal",{"id":229,"title":230,"source":231,"logo":14,"time":65},268363,"GSK acquires RAPT Therapeutics for $2.2bn","https://finance.yahoo.com/news/gsk-scoops-rapt-therapeutics-2-124311225.html",{"id":233,"title":234,"source":235,"logo":5,"time":65},268366,"Rapt Therapeutics Acquired by GSK for $2.2 Billion, Shares Surge Over 60%","https://intellectia.ai/news/stock/rapt-therapeutics-acquired-by-gsk-for-22-billion-shares-surge-over-60",{"id":237,"title":238,"source":239,"logo":5,"time":65},268365,"GSK to Acquire RAPT Therapeutics in Cash Merger","https://www.tipranks.com/news/company-announcements/gsk-to-acquire-rapt-therapeutics-in-cash-merger",{"id":241,"title":72,"source":242,"logo":33,"time":65},268389,"https://www.eveningnews24.co.uk/news/national/25779311.gsk-acquiring-firm-developing-food-allergy-treatment-1-6bn-deal/",{"id":244,"title":63,"source":245,"logo":40,"time":65},268391,"https://www.livemint.com/market/stock-market-news/rapt-therapeutics-stock-surges-63-in-pre-market-trade-on-nasdaq-after-gsks-2-2-billion-acquisition-deal-11768900659927.html",{"id":247,"title":72,"source":248,"logo":37,"time":65},268390,"https://www.becclesandbungayjournal.co.uk/news/national/25779311.gsk-acquiring-firm-developing-food-allergy-treatment-1-6bn-deal/",{"id":250,"title":251,"source":252,"logo":5,"time":65},268397,"$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)","https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-rapt-therapeutics-inc-nasdaq-rapt-302665648.html",{"id":254,"title":255,"source":256,"logo":48,"time":65},268396,"GSK to buy RAPT Therapeutics in deal valued at $2.2B (GSK:NYSE)","https://seekingalpha.com/news/4540273-gsk-to-buy-rapt-therapeutics-in-deal-valued-at-2_2b",{"id":258,"title":259,"source":260,"logo":18,"time":65},268399,"GSK to Acquire Rapt for $2.2B, Adding Food Allergy Candidate to Pipeline","https://www.genengnews.com/topics/translational-medicine/gsk-to-acquire-rapt-for-2-2b-adding-food-allergy-candidate-to-pipeline/",{"id":262,"title":263,"source":264,"logo":19,"time":65},268398,"Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK","https://www.manilatimes.net/2026/01/21/tmt-newswire/globenewswire/forbion-announces-second-exit-from-forbion-growth-fund-iii-following-22-billion-acquisition-of-rapt-therapeutics-by-gsk/2262207",{"id":266,"title":267,"source":268,"logo":24,"time":65},268393,"Big drug company makes $2.2 billion play for Peninsula biopharma, food allergy drug","https://www.bizjournals.com/sanfrancisco/news/2026/01/20/food-allergy-gsk-rapt-therapeutics-ozureprubart.html",{"id":270,"title":271,"source":272,"logo":44,"time":65},268392,"GSK to acquire US-based biopharma company RAPT Therapeutics via a $2.2 billion deal — Details here","https://www.livemint.com/companies/news/gsk-to-acquire-us-based-biopharma-company-rapt-therapeutics-via-a-2-2-billion-deal-details-here-11768898683112.html",{"id":274,"title":275,"source":276,"logo":17,"time":65},268395,"GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal","https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/",{"id":278,"title":279,"source":280,"logo":47,"time":65},268394,"RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate (RAPT)","https://seekingalpha.com/article/4861258-rapt-therapeutics-a-buy-as-gsk-acquisition-highlights-long-acting-ige-candidate","#8d7888ff","#8d78884d",1769160719455]